Overview

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.
Phase:
Phase 3
Details
Lead Sponsor:
Chelsea Therapeutics
Collaborator:
Chiltern International Inc.
Treatments:
Dopamine
Dopamine Agents
Droxidopa